Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Pegcetacoplan in ALS
2019-003797-10Phase 2Terminated
- Sponsor
- Apellis Pharmaceuticals
- Start
- Sep 2020
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: Combined Assessment of Function and Survival (CAFS) rank score at Week 52. Started Sep 2020; status: terminated.
02
Drugs
pegcetacoplan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-003797-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003797-10.